Vandetanib, a selective oral inhibitor of VEGFR, EGFR, and RET [159,160], has been reported to block the enzymatic activity of RET-derived oncoproteins and decrease the proliferation of a RET-mutant MTC cell line in vitro [161,162]. Here, RET is linked to medullary thyroid gland carcinoma.